Travere Therapeutics, Inc. (TVTX) Financial Statements
Travere Therapeutics, Inc. (TVTX) reported trailing twelve-month revenue of $591.3M (up 77.1% year on year) and net income of -$43.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $92.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TVTXTravere Therapeutics, Inc.Follow TVTX — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.2 | 175.3 | 198.3 | 131.8 | 109.5 | 145.2 | 233.2 | 490.7 | 591.3 | |
| Gross profit | 158.7 | 170.1 | 192.2 | 128.0 | 105.0 | 133.8 | 225.4 | 480.4 | — | |
| Research & development | 123.8 | 141.0 | 131.8 | 201.2 | 7.5 | 245.0 | 217.5 | 206.0 | 227.1 | |
| Operating income | -80.0 | -137.4 | -176.2 | -199.4 | -319.8 | -388.1 | -323.8 | -62.8 | -40.5 | |
| Pre-tax income | -101.9 | -146.4 | -188.8 | -216.9 | -331.2 | -376.1 | -320.5 | -49.3 | -67.1 | |
| Income tax | 0.8 | -0.0 | -19.4 | 0.4 | 0.3 | 0.2 | 0.1 | 1.0 | 0.6 | |
| Net income | -102.7 | -146.4 | -169.4 | -180.1 | -278.5 | -111.4 | -321.5 | -25.5 | -43.5 | |
| Diluted EPS ($) | -2.54 | -3.46 | -3.56 | -3.01 | -4.37 | -1.50 | -4.08 | -0.29 | -0.43 | |
| Diluted shares (mn) | 40.4 | 42.3 | 47.5 | 59.8 | 63.8 | 74.3 | 78.9 | 89.2 | — |
USD millions · SEC XBRL
Travere Therapeutics, Inc. — questions
- What is Travere Therapeutics, Inc.'s revenue?
- $591.3M over the twelve months to 2026-06-30, up 77.1% year on year, from its 10-Q and 10-K filings.
- What is Travere Therapeutics, Inc.'s net income?
- -$43.5M over the twelve months to 2026-06-30.
- What is Travere Therapeutics, Inc.'s free cash flow?
- $92.7M over the twelve months to 2026-06-30.
- What are Travere Therapeutics, Inc.'s diluted earnings per share?
- $-0.43 over the twelve months to 2026-06-30.
Every figure on this page comes from Travere Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.